Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 13/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.40 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.40 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2637157 | 0.93 | PTK2 (0.44) | PTK2AURKASTK17AGSK3AGSK3B | |
| SCHEMBL2636864 | 0.84 | PTK2 (0.42) | PTK2AURKASTK17AKDR | |
| SCHEMBL2636876 | 0.83 | AURKA (0.47) | PTK2AURKASTK17AGSK3AGSK3B | |
| SCHEMBL1917462 | 0.83 | FFAR1 (0.52) | PTK2AURKASTK17AGSK3AGSK3B | |
| SCHEMBL1627493 | 0.82 | AURKA (0.52) | PTK2AURKASTK17AGSK3AGSK3B | |
| SCHEMBL2637158 | 0.81 | PTK2 (0.46) | PTK2AURKASTK17AGSK3AGSK3B | |
| SCHEMBL2637298 | 0.81 | LRRK2 (0.50) | PTK2 | |
| SCHEMBL2636874 | 0.81 | AURKA (0.46) | PTK2AURKASTK17AGSK3AGSK3B | |
| SCHEMBL2032399 | 0.80 | PTK2 (0.44) | PTK2AURKASTK17AGSK3AGSK3B | |
| SCHEMBL2035702 | 0.80 | PTK2 (0.44) | PTK2AURKASTK17AGSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438056-B1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS LLC (US) | 2017-12-20 | — | — | EP | disclosed |
| US-9096624-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2013-09-05 | — | — | US | disclosed |
| EP-2438056-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010141406-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | PTK2 2/4885AURKA 186/4885STK17A 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.